Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02274493
Other study ID # 2013-0232
Secondary ID NCI-2015-00616
Status Completed
Phase N/A
First received
Last updated
Start date July 8, 2015
Est. completion date March 7, 2018

Study information

Verified date March 2019
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to learn more about the safety and feasibility of using the Da Vinci Robotic Surgical system in procedures that harvest the latissimus dorsi muscle (a back muscle below your shoulder) for reconstructive procedures.


Description:

If participant is found to be eligible to take part in this study, and participant agrees, participant's screening, reconstructive surgery, and follow-up appointments will be scheduled over multiple visits, as listed in this consent form. All procedures will be performed on days in which standard of care procedures would already be performed.

If it is determined that participant is eligible, the following will be performed before the surgery:

- The study doctor or a member of the research team will review participant's medical information and ask participant questions about participant's medical history and demographic information.

- Participant will have a physical exam.

- Participant will be evaluated by a Physical Therapist to test participant's range of motion and strength.

- Participant will complete a questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion. This information will be used to compare with the results after the surgery. This will take about 5 minutes to complete.

- Photographs and/or videos of the surgical site will be taken.

- If participant can become pregnant, participant will have a urine pregnancy test. To take part in this study, participant must not be pregnant.

Surgery Study Visit (2):

At this visit, participant's reconstructive surgery will be performed using a robot, called the Da VinciĀ® Robotic Surgical System. The reconstructive surgery is considered to be standard of care. Participant will be asked to sign a separate consent form that discusses the possible benefits and risks of the standard of care surgical procedure in more detail, including information about any anesthetic participant will be given for the surgery.

A standard muscle harvest procedure takes about 2 hours. A muscle harvest procedure with the robotic system is expected to take longer than the standard surgery. The total procedure time will vary for each patient depending on the type of muscle harvest procedure and other factors in the operating room. The total time to complete the muscle harvest and reconstruction will take about 4 hours. Photographs and/or videos of the surgical site will be taken.

Participant will remain in the hospital for 3-4 days after the surgery is complete for observation. After participant is discharged from the hospital, participant will need to return within 2 weeks for participant's first follow-up examination.

Follow-Up Study Visits (3-6):

After participant has been discharged from the hospital, participant will have 4 follow-up visits.

The first follow up visit will take place within two weeks after participant is discharged . The second follow-up visit will be between 2-4 weeks, the third follow up visit will be between 1-3 months and the fourth follow up will be between 3-6 months after participant is discharged.

The following tests and procedures will be performed at each follow-up visit:

- The study doctor will check the surgery site(s).

- Participant's overall health status will be checked.

- Participant will be evaluated by a Physical Therapist to test participant's range of motion and strength.

- Photographs and/or videos of the surgical site may be taken.

- Participant will complete the questionnaire about pain and participant's shoulder, arm, and hand range of motion. This information will be used to compare with the results from before the surgery.

Length of Study Participation:

Participation on the study will be over after the follow-up visits.

This is an investigational study. The use of the Da VinciĀ® Robotic Surgical System for surgery in the thorax (part of the upper body) is FDA approved and commercially available at this time. However, the system has not been FDA cleared specifically for use in latissimus dorsi muscle harvest procedures. The use of the DaVinci Robotic Surgical System for this type of reconstructive surgery has not been performed in live humans and is what researchers are investigating for this study.

Up to 15 patients will take part in this study. All will be enrolled at MD Anderson.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date March 7, 2018
Est. primary completion date March 7, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. The subject must be equal to or greater than 18 years of age.

2. The subject must be willing and able to provide informed consent.

3. The subject is willing and able to comply with the study protocol.

4. The subject is undergoing one of the following reconstructive procedures that requires latissimus dorsi muscle harvest: a. Post-mastectomy breast reconstruction procedure (either nipple or skin sparing) in which a female subject needs additional muscle coverage over an implant, but does not need additional skin (i.e., patient is a candidate for a pedicled latissimus dorsi muscle flap procedure); b. Scalp reconstruction procedure in which the subject needs a free latissimus dorsi muscle flap for wound coverage; c. Upper extremity reconstruction procedure in which the subject needs a free latissimus dorsi muscle flap for wound coverage; or, d. Lower extremity reconstruction procedure in which the subject needs a free latissimus dorsi muscle flap for wound coverage.

5. The subject agrees to follow-up examinations out to 6 months post-treatment.

Exclusion Criteria:

1. The subject has a BMI > 35.

2. The subject has a history of significant bleeding disorders.

3. The subject is diabetic.

4. The subject is known or suspected to be pregnant or lactating.

5. The subject has a history of peripheral vascular disease.

6. The subject is a current smoker (has smoked within 4 weeks prior to surgery).

7. The subject has had prior back or axillary surgeries which could compromise the blood supply of the flap.

Study Design


Intervention

Device:
da Vinci® Robotic Surgical System
Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
Procedure:
LD muscle flap harvest procedure
Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
Reconstructive surgery
Reconstructive surgery is considered to be standard of care.
Behavioral:
Questionnaires
Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Assessed for Donor Site Complications and Muscle Flap Viability Muscle flap viability was determined by measuring the blood flow into and out of the muscle flap with a hand held Doppler after muscle harvest was complete Participants were followed for up to a total of 6 months post-operatively
Primary Number of Participants With LD Muscle Flap Viability Following Robotic-Assisted Harvest Procedure Participants were followed for up to a total of 6 months post-operatively
Secondary Evaluation of Donor Site Complications Through 6 Months Post-procedure The participants listed were evaluated for donor site complication. Participants were followed for up to a total of 6 months post-operatively
Secondary LD Muscle Flap Failure Through 6 Months Post-procedure Flap failure is defined as irreversible arterial and venous thrombosis detected by implantable or surface doppler signal. Participants were followed for up to a total of 6 months post-operatively
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients